title: Metabolic effects of nandrolone decanoate and resistance training in men with HIV.
abstract: Thirty human immunodeficiency virus (HIV)-infected men were randomized to a high dose of nandrolone decanoate weekly (group 1) or nandrolone plus resistance training (group 2) for 12 wk. For the two groups, nandrolone had no significant effects on total cholesterol, LDL cholesterol, LDL phenotype, or fasting triglycerides, although triglycerides decreased by 66 +/- 124 mg/dl for the entire population (P = 0.01). Group 2 subjects had a favorable increase of 5.2 +/- 7.7A in LDL particle size (P = 0.03), whereas there was no change in group 1. Lipoprotein(a) decreased by 7.3 +/- 6.8 mg/dl for group 1 (P = 0.002) and by 6.9 +/- 8.1 for group 2 (P = 0.013). However, HDL cholesterol decreased by 8.7 +/- 7.4 mg/dl for group 1 (P < 0.001) and by 10.6 +/- 5.9 for group 2 (P < 0.001). Percentages of HDL(2b) (9.7-12 nm) and HDL(2a) (8.8-9.7 nm) subfractions decreased similarly for the two groups, whereas HDL(3a) (8.2-8.8 nm) and HDL(3b) (7.8-8.2 nm) increased in the groups during study therapy (P < or = 0.02 for all comparisons). There was no evidence of a decreased insulin sensitivity in either group, whereas fasting glucose, fasting insulin, and homeostasis model assessment improved in group 2 (P < 0.05). These metabolic effects were favorable (other than for HDL), but changes were generally transient (except for HDL in group 2), with measurements returning to baseline 2 mo after the interventions were completed.
authors.affiliation: Departments of Medicine, Biokinesiology and Physical Therapy, and of Biometry, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA. fsattler@usc.edu
authors.forename: Fred R
authors.initials: FR
authors.lastname: Sattler
authors.forename: E Todd
authors.initials: ET
authors.lastname: Schroeder
authors.forename: Michael P
authors.initials: MP
authors.lastname: Dube
authors.forename: S Victoria
authors.initials: SV
authors.lastname: Jaque
authors.forename: Carmen
authors.initials: C
authors.lastname: Martinez
authors.forename: Patricia J
authors.initials: PJ
authors.lastname: Blanche
authors.forename: Stanley
authors.initials: S
authors.lastname: Azen
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Krauss
mesh_terms: D000328:Adult; D000728:Androgens / Q000008:administration & dosage / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001823:Body Composition / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002149:Energy Intake; D004734:Energy Metabolism / Q000187:drug effects; D015444:Exercise; D015658:HIV Infections / Q000378:metabolism* / Q000628:therapy*; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D017270:Lipoprotein(a) / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000077603:Nandrolone Decanoate; D010316:Particle Size; D014280:Triglycerides / Q000097:blood
chemical_list: D000728:Androgens; D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007328:Insulin; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D014280:Triglycerides; D009277:Nandrolone; D002784:Cholesterol; D000077603:Nandrolone Decanoate